Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,004 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dementia Clear all
Completed Phase 3 Interventional Results available

Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease

NCT00566501
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 91 Years
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 29, 2026, 2:53 AM EDT
Terminated Not applicable Interventional Results available

Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer's

NCT02769000
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
10 GY in 5 daily fractions, 20 GY in 10 daily fractions
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
55 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 29, 2026, 2:53 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

ALSENLITE: Senolytics for Alzheimer's Disease

NCT04785300
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Dasatinib, Quercetin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 29, 2026, 2:53 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

NCT01079819
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BMS-708163, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Cypress, California • Glendale, California • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Oct 29, 2026, 2:53 AM EDT
Completed No phase listed Observational

Brain Attack Surveillance in Corpus Christi--Cognitive (BASIC-Cognitive)

NCT03403257
View directory record Official record
Conditions
Dementia, Dementia Alzheimers, Dementia, Vascular, Dementia, Mixed
Interventions
No interventions
Other
Lead sponsor
University of Michigan
Other
Eligibility
65 Years and older
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 29, 2026, 2:53 AM EDT
Terminated Phase 1 Interventional

Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

NCT01072812
View directory record Official record
Conditions
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
Interventions
Posiphen® tartrate capsules
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 29, 2026, 2:53 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease

NCT04057807
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LPS
Drug
Lead sponsor
Yale University
Other
Eligibility
55 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 29, 2026, 2:53 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Dynamic Light Scattering Ocular Measurement in the Detection of Dementia

NCT06613971
View directory record Official record
Conditions
Dementia, Dementia Alzheimer Type
Interventions
Not listed
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Coconut Creek, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 29, 2026, 2:53 AM EDT
Completed Not applicable Interventional Results available

Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Dementia

NCT02210286
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Magtein
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 29, 2026, 2:53 AM EDT
Terminated Phase 1 Interventional

Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)

NCT06673069
View directory record Official record
Conditions
Alzheimer Disease, Down Syndrome
Interventions
ION269
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
35 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Indianapolis, Indiana • Kansas City, Kansas • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 29, 2026, 2:53 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses

NCT05877196
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Cognitive Impairment, Cognitive Decline, Memory Loss, Memory Impairment
Interventions
Moderate Intensity Continuous Training (MICT), Chair-based Stretch, High-Intensity Interval Training (HIIT), Combined Aerobic Resistance Exercise (CARE)
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
65 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 29, 2026, 2:53 AM EDT
Completed Not applicable Interventional Results available

Patient Priorities Care Among Persons Living With Mild Cognitive Impairment and Dementia

NCT06001775
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment
Interventions
Patient Priorities Care
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Indianapolis, Indiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 29, 2026, 2:53 AM EDT
Completed Not applicable Interventional

Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone

NCT00392912
View directory record Official record
Conditions
Alzheimer's Disease, Hypogonadism
Interventions
AndroGel (Solvay Pharmaceuticals)
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
55 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 29, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

NCT03518073
View directory record Official record
Conditions
Alzheimer Disease (AD)
Interventions
Zagotenemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
49
States / cities
Phoenix, Arizona • Tucson, Arizona • Encino, California + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 29, 2026, 2:53 AM EDT
Completed Phase 1 Interventional

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease

NCT01966666
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TPI-287 2 mg/m2, TPI-287 6.3 mg/m2, TPI-287 20 mg/m2, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 82 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 29, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects

NCT03581305
View directory record Official record
Conditions
Depression, HIV Infections, HIV-Associated Cognitive Motor Complex
Interventions
18F-FDOPA, 11C-DASB
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 29, 2026, 2:53 AM EDT
Enrolling by invitation Phase 4 Interventional

Pilot Study of StudyU for N-of-1 Trials in HFrEF Patients (N-of-1 App)

NCT07252310
View directory record Official record
Conditions
HFrEF - Heart Failure With Reduced Ejection Fraction, Heart Failure, Heart Failure, Systolic, Heart Diseases
Interventions
beta blockers, StudyU Application
Drug · Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 29, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease

NCT00838110
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
93
States / cities
Mobile, Alabama • Northport, Alabama • Little Rock, Arkansas + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 29, 2026, 2:53 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment

NCT01876823
View directory record Official record
Conditions
Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
Interventions
es-citalopram, Memantine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 29, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

Daridorexant to Prevent Delirium After Heart Surgery

NCT06630390
View directory record Official record
Conditions
POSTOPERATIVE DELIRIUM, POSTOPERATIVE COGNITIVE DECLINE
Interventions
Daridorexant 50 mg, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 29, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Brain Vascular and Neurocognitive Health

NCT06497413
View directory record Official record
Conditions
Cognitive Decline, Cognitive Dysfunction, Alzheimer Disease, Vascular Disease, Peripheral
Interventions
Transcranial Photobiomodulation, Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus) with no light administered
Device
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 29, 2026, 2:53 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Cholinergic Health After Menopause (CHAMP)

NCT04129060
View directory record Official record
Conditions
Postmenopausal Symptoms, Aging, Alzheimer Disease
Interventions
Cholinergic antagonist
Drug
Lead sponsor
University of Vermont
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Nashville, Tennessee • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 29, 2026, 2:53 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

NCT00663936
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
T-817MA, Placebo
Drug
Lead sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Industry
Eligibility
50 Years to 90 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Garden Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 29, 2026, 2:53 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease

NCT02547818
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ALZT-OP1a, ALZT-OP1b, Placebo ALZT-OP1a, Placebo ALZT-OP1b
Drug · Other
Lead sponsor
AZTherapies, Inc.
Industry
Eligibility
55 Years to 79 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
69
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 29, 2026, 2:53 AM EDT